CYP2D6 genotyping was carried out by XbaI restriction fragment length
polymorphism analysis and polymerase chain reaction in 168 healthy Dan
ish volunteers, 77 extensive metabolizers (EM) and 91 poor metabolizer
s (PM) of sparteine. All EM were genotyped correctly as heterozygous o
r homozygous for the functional (wild type) gene, DG-wt. However, the
DG-wt gene was apparently also present in 11 (12%) of the PM who accor
dingly were incorrectly genotyped as EM. The specificity of genotyping
PM thus was 100% but the sensitivity was only 88%. The most common al
lele was the DG-wt with an apparent frequency of 0.741 (0.026) in the
Danish population and the second most common allele was the D6-B with
an apparent frequency of 0.194 (0.024). The median (range) of the spar
teine metabolic ratio (MR) in 47 homozygous D6-wt EM was 0.28 (0.11-4.
10) and the corresponding value in heterozygous EM was 0.36 (0.11-9.10
). The median difference was 0.09 (95% confidence interval: 0.02-0.16)
. CYP2D6 phenotyping is a promising tool in tailoring the individual d
ose of tricyclic antidepressants, some neuroleplics and some antiarrhy
thmics. However if the genotype test could be improved with regard to
both sensitivity in PM and the ability to predict CYP2D6 activity in E
M then it would be of even greater clinical value in therapeutic drug
monitoring.